ArticleCarcinogenesis2026
Stromal NNMT overexpression as an independent prognostic biomarker in lung adenocarcinoma and breast carcinoma.
Yanzhong Wang, Yiping Wu, Shuyang Zheng, Xiaotian Yan, Xingtong Yu, Yuzhen Gao, Shuduo Xie, Zhinong Jiang, Rui An, Guoli Li and 4 more
Abstract read
In one paragraphArticle in Carcinogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Yanzhong WangDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.ORCID 0000-0001-8372-3762 Yiping WuDepartment of Clinical Laboratory, Zhuji Second People's Hospital, Zhuji, Zhejiang 311811, China.
Shuyang ZhengDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.
Xiaotian YanDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.
Xingtong YuDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.
Yuzhen GaoDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.ORCID 0000-0001-7485-5237 Shuduo XieDepartment of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China.
Zhinong JiangDepartment of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.ORCID 0000-0003-4040-0407 Rui AnDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.ORCID 0000-0002-3663-3825 Guoli LiDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.
Jun YangDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.ORCID 0000-0002-2921-7372 Qingchao TongDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.ORCID 0009-0000-3319-580X Xinyou XieDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.ORCID 0000-0002-1215-7465 Jun ZhangDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.ORCID 0000-0002-2613-3165 Funding
Health Bureau Foundation of Zhejiang Province 2022KY1186Health Bureau Foundation of Zhejiang Province 2024KY1104Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province 2022E10018Key Research and Development Program of Zhejiang Province 2019C03021Key Research and Development Program of Zhejiang Province 2022C03037National Natural Science Foundation of China 81271914National Natural Science Foundation of China 81972012National Natural Science Foundation of China 82172362National Natural Science Foundation of China 82472351Natural Science Foundation of Zhejiang Province LY22H200002Natural Science Foundation of Zhejiang Province LY24H200001Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0509504
6 · The paper itselfAbstract
This study investigated the expression profile and prognostic significance of nicotinamide N-methyltransferase (NNMT) in pan-cancer stroma, with focused validation in lung adenocarcinoma (LUAD) and breast carcinoma (BC). Integrated analysis of Genotype-Tissue Expression and The Cancer Genome Atlas databases revealed tumor-specific NNMT mRNA upregulation in these malignancies. Subsequently, the relationship between NNMT mRNA expression levels and clinical parameters across multiple cancer types was examined, with particular emphasis on LUAD, BC, and CRC. Single-cell RNA sequencing data further revealed elevated NNMT expression specifically within stromal compartments, with fibroblasts exhibiting the highest NNMT expression levels among stromal cell populations. Protein-level validation using the Human Protein Atlas database, the National Cancer Institute's Proteomics Data Commons, and the quantitative immunohistochemistry of our independent clinical cohorts demonstrated elevated stromal NNMT protein expression, particularly in cancer-associated fibroblasts. Cox regression analysis and survival curve analysis established stromal NNMT expression as an independent prognostic factor for overall survival in LUAD and BC patients (P < .05). In conclusion, high stromal NNMT levels correlated with poor prognosis, establishing it as a promising biomarker for risk stratification in LUAD and BC.
Indexed as
Adenocarcinoma of LungBiomarkers, TumorBreast NeoplasmsLung NeoplasmsNicotinamide N-MethyltransferaseAgedCancer-Associated FibroblastsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisStromal CellsBiomarkers, TumorNicotinamide N-MethyltransferaseNNMT protein, humanbreast carcinomaindependent prognostic biomarkerlung adenocarcinomaNNMTtumor stromal cell
Identifiers
PMID41913584
PMCPMC13174943
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390